Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Industry: Biotechnology

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Current Quote*
Last: $1.700
Change: 0.000
Book: $2.494
Volume: 1,242,641

As Of: 07/14 15:46 ET
*Quotes delayed by 20min.

Graphs for CTXR


3 Month Graph


6 Month Graph


1 Year Graph